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Tony Pawson got his Ph.D. in 1976
after working at the ICRF with Alan
Smith. He did his postdoc in
Berkeley, and then moved to the
University of British Columbia in
Vancouver to start his own lab.
When he realized that it actually
rains most of the time on the
Canadian west coast, he moved to
Toronto as a founding member of
the Samuel Lunenfeld Research
Institute of Mt. Sinai Hospital,
where he has been ever since.
During his Ph.D. he became
interested in how overexpression of
a single oncogenic protein could
elicit profound changes in many
different aspects of cellular
behaviour; in looking for common
features of signaling pathways he
later stumbled on the SH2 domain.
For the last 25 years he has been
trying to understand how such
pathways are organized, and what
they do in cells and organisms.
What is your favourite paper?
Martin, G.S. (1970). Rous sarcoma
virus: a function required for the
maintenance of the transformed
state. Nature 227, 1021–1023.
Steven Martin isolated a mutant of
Rous sarcoma virus (RSV) which
was temperature-sensitive for its
ability to induce malignant
transformation of infected cells, but
not for viral replication. This
suggested that the entire
cancerous phenotype of an RSV-
infected cell could be attributed to
a dedicated oncogene, later named
v-Src. The temperature-sensitive
phenotype was subsequently found
to result from inactivation of the
mutant v-Src tyrosine kinase at the
non-permissive temperature. The
implications of this finding were
absolutely profound, and still
boggle the mind some 30 years
later. As a happy coincidence, I ran
into Steve while at the ICRF, and
was fortunate to work in his lab as
a postdoc in Berkeley.
What turned you on to biology in
the first place? I had an engaging
and enthusiastic biology teacher in
school who absolutely fascinated
me with the idea that one could
understand the biochemistry of
cells and organisms, and so get an
idea about how life worked. It was
a heady thought, and I’ve been
completely hooked ever since.
Also, I was no good at any other
job I tried. I’ve been very lucky in
my mentors, and in the places that
I ended up. Tim Hunt was one of
my undergraduate tutors at
Cambridge, and fired me up about
doing experiments. He also told me
that the most difficult part of
science can be finding the right-
sized bits of tubing to fit on
columns. I had no idea what I was
getting into when I went to ICRF for
my Ph.D., as it had very few
students at the time. It was a sink-
or-swim environment, but an
exceptionally exciting one, with
work on oncogenic viruses
revealing many of the key aspects
of malignant transformation and
molecular biology. In California I
was exposed to the early days of
cellular oncogenes, and upon
moving to Vancouver, was
fortunate to have Michael Smith as
a neighbour, and so to have access
to the technology of site-directed
mutagenesis in its infancy. Perhaps
my best stroke of good fortune was
to work closely with people like
Janet Rossant, Alan Bernstein and
Joe Culotti in Toronto, who taught
me about genetics and the
relationship of signaling processes
to development.
What are your current interests?
Unfortunately I have too many. I am
interested in several different
aspects of cell biology, and don’t
have enough discrimination to
focus (though I routinely advise
everyone else to do so). One of my
new enthusiasms is cell polarity,
because it is so fundamental to the
organization of cells and tissues.
We’re starting to learn about an
interconnected series of protein
complexes that control
polarization, and related processes
like asymmetric cell division, and
it’s going to be intriguing to know
how they actually work. I’m also
excited by the findings that
pathogenic microorganisms and
mutant cellular proteins can re-wire
signaling pathways, in effect
teaching the cell to do new things.
Using the same logic, we should be
able to experimentally — and
perhaps therapeutically — re-wire
cellular signaling to modify cellular
behavior in pre-determined ways,
and I’d love to see this happen.
Now that we understand a lot
about the bits and pieces through
which signaling systems are put
together, the challenge is to
understand how they function in
unison to induce complex cellular
behaviour. Even more daunting is
the question of how tissues and
organs form. Hence the current
vogue for systems biology.
What are the big challenges in
your field? We’ve been arguing for
at least 30 years that if we
understood the molecular basis for
malignant transformation, this
would lead to new therapies for
cancer. Drugs such as Gleevec, an
inhibitor of the Abl and Kit kinases
in chronic myelogenous leukemia
and gastro-intestinal stromal
tumours, respectively, are starting
to validate this logic, but it is very
early days for such new treatments.
There is a tremendous challenge in
translating our molecular data
about cellular function into useful
remedies for disease, while at the
same time bearing in mind that our
knowledge about how cells work is
still very superficial.
What advice would you offer
someone wondering whether to
start a career in biology? Only do
it if you’re really passionate about
it, and have an aptitude for it. If
that’s the case, don’t hesitate.
Follow your nose about what is
interesting. Look for subjects
where there are important
questions that are not being
addressed. Curiously, the more you
know about a field, the more
difficult it becomes to spot what’s
missing, so if you find yourself
asking “how come no-one knows
the answer to that?”, you may have
hit on a good project. Don’t be
afraid of making mistakes, as you
will anyway; you can’t learn to ride
a bike without falling off.
What will be the impact of ‘big
biology’? There’s a lot of
unnecessary worry about ‘big
biology’. For the foreseeable future,
I believe the most entertaining and
productive aspect of biology will
remain figuring out the specifics of
how particular cellular processes
or machines actually work. Most
biologists love this kind of scientific
sleuthing. At the same time, there
are great rewards to be had from
taking basic ideas, and exploring
them on a large scale, especially if
we want to know how the whole
cell (or tissue, or organism) is put
together. I think there’s a tendency
to equate ‘big’ with mindless,
which is far from the case. Large
datasets and innovative techniques
challenge us to think in new ways,
which can’t be bad. These broad
experiments also force us to work
cooperatively, which is something
we’re not very used to.
Any views on journals and
publication? If your work is
significant and worthwhile, people
will find it regardless of where it’s
published, especially in this age of
electronic browsing.
Groundbreaking work may be hard
to get into the ‘top’ journals,
because it doesn’t fit established
norms; by the same token, if you
publish something in a ‘top’ journal
that’s trendy but isn’t really much
good, it doesn’t help you in the
long run. The main question is
whether a paper stands the test of
time. There’s a tendency on the
part of students to view publication
in anything other than the ‘top’
journals as a failure, and I think this
is a huge mistake. It seems to me
that electronic publishing is
starting to level the playing field,
and other web-based forms of
publication are springing up, which
is very healthy. I believe that peer
review is important, but is currently
overdone — it is not uncommon for
a referee to see the same paper
through three rounds of revision.
This is a waste of time, and runs
the risk that the authors end up
publishing what the reviewers or
editors want to see, rather than the
paper the authors actually have in
mind. The question is how to
maintain a significant level of peer
review, while making the options
for publication as diverse as
possible.
Samuel Lunenfeld Research Institute,
Mt. Sinai Hospital, 600 University
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The philosopher, Daniel Dennett,
has been the doyen amongst his
profession for many biologists
with his series of popular books
looking at questions thrown up by
Darwin’s work. How does natural
selection lead to such things as
consciousness and minds? In
recent years his books on such
issues have earned him the
respect of a formidable list of
academics. Philosopher Richard
Rorty praised his ‘extraordinarily
lucid argumentation’. Steve Pinker
credited his ‘twinkling wit’ and
Richard Dawkins referred to his
writing as a ‘torrent of stimulating
thought’.
But his unstinting materialism,
which he now calls naturalism,
has roused many critics of his
approach. The question hangs
around the issue of determinism.
This is the issue of Dennett’s new
book. As he points out, educated
people today are often trapped in
a strange kind of double-think on
the topic. Officially, they believe
physical science calls for
determinism, which proves they
have no control over their lives.
But in actual living, most of the
time they do assume they have
this control. They ignore their
supposedly scientific beliefs but
these can still cause deep
underlying anxiety, confusion,
guilt and a sense of futility.
“The proper job for
philosophers here is to clarify and
unify the often warring
perspectives into a single vision of
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A biologist’s thinking man
Philosopher Daniel Dennett believes he has an evolutionary explanation
for one of biology’s most difficult concepts: free will. Nigel Williams
reports on his latest book. 
Material gain: ‘Philosophical investigations are not superior to, or prior to, investiga-
tions in the natural sciences.’ Freedom Evolves by Daniel Dennett is published by Viking
in the US ($24.95) and by Allen Lane in the UK (£20).
